COMMUNIQUÉS West-GlobeNewswire

Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™
08/01/2026
As part of the branding process, Polyrizon conducted comprehensive trademark screening across the U.S. and European markets Raanana, Israel, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ [...]
Marius Pharmaceuticals to Initiate Study Evaluating KYZATREX® (testosterone undecanoate) CIII Capsules in Men Ages 65–80
08/01/2026
RALEIGH, N.C., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, Inc. today announced the company will initiate a new post-marketing clinical study for potential label expansion evaluating KYZATREX ® ( [...]
Onco3R Therapeutics Appoints Lawrence Blatt as Chair of the Board for Onco3R Therapeutics
08/01/2026
Leuven , Belgium. January 8, 2026 . Onco3R Therapeutics, a clinical-stage immunology and oncology biotech company dedicated to transforming patients’ lives with best-in-class medicines, today announced the appointment [...]
Engitix Announces $25 Million Series A Extension Financing by Existing Investor Mike Platt to Advance ECM-Targeted Therapeutics in Solid Tumors and Fibrosis
08/01/2026
Company has built one of the largest proprietary extracellular matrix (ECM) datasets spanning fibrosis and solid tumors LONDON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Engitix Ltd (“Engitix”), a biotech company targeting the [...]
PathAI and University Hospital Zurich Announce Collaboration to Deploy AISight® Dx and AIM-TumorCellularity for Routine Molecular Pathology Workflows
08/01/2026
BOSTON, Mass. and ZURICH, Switzerland, Jan. 08, 2026 (GLOBE NEWSWIRE) -- PathAI, a global leader in AI-powered pathology, today announced a strategic collaboration with University Hospital Zurich (USZ) to deploy AISight [...]
Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference
08/01/2026
Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential market of $7B+ in the U.S. alone Multiple milestones anticipated from late- [...]
NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is Being Developed as a Disease-modifying Treatment for ALS/MND and Parkinson’s
08/01/2026
STEVENAGE, United Kingdom, Jan. 08, 2026 (GLOBE NEWSWIRE) -- NRG Therapeutics Ltd. (“NRG”), a clinical stage neuroscience company targeting a novel mechanism to rectify mitochondrial dysfunction in neurodegenerative [...]
Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference
08/01/2026
ZUG, Switzerland, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential market of $7B+ in the U.S. [...]
Rakovina Therapeutics and Variational AI Expand Collaboration to Advance Next-Generation ATR Inhibitors
08/01/2026
VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina”), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug [...]
EnteroBiotix announces positive Phase 2 TrIuMPH results supporting EBX-102-02 as a potential first-in-class, oral, full-spectrum microbiome therapy for irritable bowel syndrome
08/01/2026
Clinically meaningful improvements in global IBS symptom severity observed as early as Week 1 and sustained through Week 7, with EBX-102-02 outperforming placebo throughout the study (final assessment at Week 7) Durable [...]
Agomab Announces Positive Phase 1 Interim Results with AGMB-447 in Healthy Participants and Initiation of Idiopathic Pulmonary Fibrosis Cohort
08/01/2026
-- Interim data from Phase 1 with single and multiple ascending doses show no safety signals and a generally favorable tolerability profile of AGMB-447 in healthy participants -- -- Pharmacokinetic profile in healthy [...]
Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in Malignant Pleural Mesothelioma (MPM) and Epithelioid Hemangioendothelioma (EHE)
08/01/2026
ORION CORPORATION PRESS RELEASE 8 JANUARY 2026 at 12.00 EET Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in Malignant Pleural Mesothelioma (MPM) and Epithelioid Hemangioendothelioma (EHE) [...]
Human Appeal’s new subsidiary, The Waqf Fund, launched into $700 billion global market
08/01/2026
To promote charitable funds for long-term humanitarian projects MANCHESTER, United Kingdom, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Leading UK humanitarian aid charity, Human Appeal, today announces the launch of a new [...]
Aclarion Provides 2025 Update and 2026 Corporate Outlook
08/01/2026
Quarterly Nociscan scan volumes increased 114% year-over-year in Q4 2025 Annual Nociscan scan volumes increased 69% year-over-year in 2025 Debt-free balance sheet with $12.0 million in cash as of December 31, 2025, [...]
Telix to Present Pipeline and Commercial Portfolio Overview at J.P. Morgan Healthcare Conference
08/01/2026
MELBOURNE, Australia and INDIANAPOLIS, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will [...]
Pharming Group reports preliminary 2025 revenues and announces Investor Day
08/01/2026
Leiden, The Netherlands, January 8, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its preliminary, unaudited revenues for the full year 2025 and plans [...]
Basilea provides portfolio update and outlook
08/01/2026
Clinical portfolio strengthened through the in-licensing of phase 3-ready antibiotic ceftibuten-ledaborbactam Fosmanogepix second phase 3 study initiated; two phase 3 studies in invasive fungal infections progressing as [...]
Eleva appoints Erich Rajkovic as new Chief Business Officer
08/01/2026
Freiburg im Breisgau, Germany – January 8, 2026 – Eleva, a pioneer in discovering and developing previously inaccessible biologics, today announced the appointment of Dr. Erich Rajkovic, MBA, as Chief Business Officer. [...]
Tensive reports positive pivotal trial top-line results showing REGENERA™ bioresorbable device may transform breast reconstruction
08/01/2026
Clinical data from pivotal trial in patients undergoing lumpectomy confirm strong safety profile and growing performance benefits Primary safety endpoint met and encouraging secondary performance objectives at 6 months [...]

Pages